At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy
GSK has committed $270 million to gain access to early-stage assets in the cancer therapy class of antibody drug conjugates. After divesting its oncology business in 2015, the company has decided to re-enter the field, focusing on therapeutic modalities like immuno-oncology, synthetic lethality, and tumor cell targeting. They are prioritizing hematological malignancies, gynecological cancers, lung…